Texas Capital Bank Wealth Management Services’s Corcept Therapeutics CORT Stock Holding History

Texas Capital Bank Wealth Management Services’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$307K	Buy	+3,527	New	+$213K	0.02%	288

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Texas Capital Bank Wealth Management Services's CORT Position: Q2 2026 in Review

Texas Capital Bank Wealth Management Services opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 3,527 shares worth $307K. The stake represents 0.02% of the portfolio and ranks #288 among its holdings.

422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Texas Capital Bank Wealth Management Services held 3,527 shares of Corcept Therapeutics worth $307K as of Q2 2026.
Corcept Therapeutics was a new Texas Capital Bank Wealth Management Services position in Q2 2026.
Corcept Therapeutics made up 0.02% of Texas Capital Bank Wealth Management Services's portfolio in Q2 2026, its #288 holding.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Texas Capital Bank Wealth Management Services's 13F filing for Q2 2026, filed 7 Aug 2026.